Singular Immune
- Biotech or pharma, therapeutic R&D
First-in-Class in vivo CAR platform with >4 active pipelines in the fields of solid tumors, blood cancers, autoimmune diseases, and inflammatory diseases. Singular Immune is seeking equity investors for the current seed round, strategic investors/partners, or out-licensing opportunities.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}